Examining the role of specific gene signaling in colorectal cancer

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

This study is trying to understand how certain genes affect colorectal cancer to help doctors find better treatments and predict how patients will do after surgery.

Quick facts

• Study type: Observational
• Enrollment: 200 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Qianfoshan Hospital (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Jinan, Lixia)
• Trial ID: NCT05579353 on ClinicalTrials.gov

What this trial studies

This observational study focuses on understanding the roles of exosomal Circ-LRBA and the 451/CRTC2 signaling axis in colorectal cancer. It aims to investigate the molecular mechanisms underlying colorectal cancer progression and identify potential biomarkers that could aid in predicting patient prognosis. By analyzing gene expression changes in patients who have undergone radical surgical resection for colorectal cancer, the study seeks to enhance the selection of targeted therapies for better treatment outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are patients aged 18-80 who have undergone radical resection for colorectal cancer.

Not a fit: Patients with severe comorbidities, those who refuse sample collection, or those with a history of neoadjuvant therapy are unlikely to benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to the identification of new biomarkers that improve treatment selection and outcomes for colorectal cancer patients.

How similar studies have performed: While there have been studies exploring molecular targets in colorectal cancer, this specific approach focusing on the Circ-LRBA and 451/CRTC2 signaling axis is relatively novel.

Eligibility criteria

Inclusion Criteria:

1.18-80 years old.

2.18.5 \< BMI \< 27.9.

3\. The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion Criteria:

1. Those who refuse to collect samples.
2. Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
3. Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
4. Combining with distant multiple metastases of tumor

Where this trial is running

Jinan, Lixia

• The First Affiliated Hospital of Shandong First Medical University — Jinan, Lixia, China (Recruiting)

Study contacts

• Study coordinator: Jingbo Chen, doctor

Conditions Colorectal Cancer